Small Molecules Targeting Mitochondria: A Mechanistic Approach to Combating Doxorubicin-Induced Cardiotoxicity
Cardiovascular Toxicology · 2025
DOI: 10.1007/s12012-024-09941-7 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Toxicology, 2025. Verfasst von Chinmay Pal. Beteiligte Einrichtung: Department of Chemistry, Gobardanga Hindu College, North 24 Parganas, West Bengal, 743273, India. cpal@ghcollege.ac.in. Hauptthemen laut MEDLINE: Doxorubicin, Mitochondria, Heart, Heart Diseases, Antibiotics, Antineoplastic. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 167 Literaturangaben.
Abstract (Originalsprache)
Doxorubicin (Dox) is a commonly used chemotherapy drug effective against a range of cancers, but its clinical application is greatly limited by dose-dependent and cumulative cardiotoxicity. Mitochondrial dysfunction is recognized as a key factor in Dox-induced cardiotoxicity, leading to oxidative stress, disrupted calcium balance, and activation of apoptotic pathways. Recent research has emphasized the potential of small molecules that specifically target mitochondria to alleviate these harmful effects. This review provides a comprehensive analysis of small molecules that offer cardioprotection by preserving mitochondrial function in the context of doxorubicin-induced cardiotoxicity (DIC). The mechanisms of action include the reduction of reactive oxygen species (ROS) production, stabilization of mitochondrial membrane potential, enhancement of mitochondrial biogenesis, and modulation of key signaling pathways involved in cell survival and apoptosis. By targeting mitochondria, these small molecules present a promising therapeutic strategy to prevent or reduce the cardiotoxic effects associated with Dox treatment. This review not only discusses the mechanistic actions of these agents but also emphasizes their potential in improving cardiovascular outcomes for cancer patients. Gaining insight into these mechanisms can help in creating more effective strategies to safeguard the heart during chemotherapy, allowing for the ongoing use of Dox with a lower risk to the patient's cardiovascular health. This review highlights the critical role of mitochondria-targeted therapies as a promising approach in addressing DIC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Gobardanga Hindu College, North 24 Parganas, West Bengal, 743273, India. cpal@ghcollege.ac.in.
Zitieren
APA
Pal, C. (2025). Small Molecules Targeting Mitochondria: A Mechanistic Approach to Combating Doxorubicin-Induced Cardiotoxicity. Cardiovascular Toxicology. https://doi.org/10.1007/s12012-024-09941-7
Vancouver
Pal C. Small Molecules Targeting Mitochondria: A Mechanistic Approach to Combating Doxorubicin-Induced Cardiotoxicity. Cardiovascular Toxicology. 2025. doi:10.1007/s12012-024-09941-7
BibTeX
@article{Pal2025,
author = {Pal, Chinmay},
title = {Small Molecules Targeting Mitochondria: A Mechanistic Approach to Combating Doxorubicin-Induced Cardiotoxicity},
journal = {Cardiovascular Toxicology},
year = {2025},
doi = {10.1007/s12012-024-09941-7}
}
EUVIMED